Schizophrenia
Welcome,         Profile    Billing    Logout  
 86 Companies   137 Products   137 Products   85 Mechanisms of Action   4 Trials   2019 News 


«12345678910111213...3940»
  • ||||||||||  Trial completion, Enrollment change:  AHCM: Addiction Housing Case Management for Homeless Veterans (clinicaltrials.gov) -  Aug 10, 2016   
    P=N/A,  N=181, Completed, 
    Trial primary completion date: Mar 2016 --> Mar 2017 Active, not recruiting --> Completed | N=400 --> 181
  • ||||||||||  mirtazapine / Generic mfg.
    Trial completion, Trial primary completion date:  RECOVERY2: Evaluation of Mirtazapine and Folic Acid for Schizophrenia: (clinicaltrials.gov) -  Aug 3, 2016   
    P4,  N=333, Completed, 
    Trial primary completion date: May 2016 --> Sep 2016 Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Dec 2012
  • ||||||||||  Nuplazid (pimavanserin) / Acadia Pharma
    Enrollment closed, Trial primary completion date:  A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis (clinicaltrials.gov) -  Aug 2, 2016   
    P2,  N=181, Active, not recruiting, 
    Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Dec 2012 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2016
  • ||||||||||  Trial termination:  The Topical Niacin Skin Flush Test in First Episode Psychosis (clinicaltrials.gov) -  Jul 28, 2016   
    P3,  N=107, Terminated, 
    Recruiting --> Completed Recruiting --> Terminated; Unable to secure funding for second phase of study (i.e., niacin skin flush test in early psychosis patients).
  • ||||||||||  Enrollment closed, Trial primary completion date:  Fingolimod in Schizophrenia Patients (clinicaltrials.gov) -  Jul 28, 2016   
    P2,  N=40, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Aug 2016
  • ||||||||||  metformin / Generic mfg.
    Trial primary completion date:  Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness (clinicaltrials.gov) -  Jul 20, 2016   
    P4,  N=24, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Aug 2016 Trial primary completion date: Jun 2016 --> Dec 2016
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Trial suspension, Trial primary completion date:  Linagliptin in Schizophrenia Patients (clinicaltrials.gov) -  Jul 19, 2016   
    P1,  N=5, Suspended, 
    Trial primary completion date: Jun 2016 --> Jun 2017 Recruiting --> Suspended | Trial primary completion date: Oct 2016 --> Jul 2016
  • ||||||||||  Enrollment closed:  Probiotics to Prevent Relapse After Hospitalization for Mania (clinicaltrials.gov) -  Jul 14, 2016   
    P=N/A,  N=66, Active, not recruiting, 
    Recruiting --> Suspended | Trial primary completion date: Oct 2016 --> Jul 2016 Enrolling by invitation --> Active, not recruiting
  • ||||||||||  Enrollment closed:  Cognitive Remediation for First Episode of Psychosis Patients (clinicaltrials.gov) -  Jul 5, 2016   
    P=N/A,  N=40, Active, not recruiting, 
    Active, not recruiting --> Completed | N=46 --> 20 Recruiting --> Active, not recruiting
  • ||||||||||  minocycline / Generic mfg.
    Trial completion, Trial primary completion date:  MINOS: Minocycline for Schizophrenia (clinicaltrials.gov) -  Jun 30, 2016   
    P4,  N=150, Completed, 
    Trial primary completion date: Feb 2016 --> Dec 2016 Recruiting --> Completed | Trial primary completion date: Jun 2015 --> May 2016
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Effects of a Walking Program in People With Mental Disorders (clinicaltrials.gov) -  Jun 28, 2016   
    P=N/A,  N=135, Completed, 
    Recruiting --> Completed | Trial primary completion date: Jun 2015 --> May 2016 Recruiting --> Completed | N=100 --> 135 | Trial primary completion date: Dec 2015 --> Jun 2016
  • ||||||||||  Enrollment change, Trial termination:  Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia (clinicaltrials.gov) -  Jun 22, 2016   
    P1/2,  N=18, Terminated, 
    Recruiting --> Active, not recruiting N=72 --> 18 | Recruiting --> Terminated
  • ||||||||||  Trial completion, Trial primary completion date:  Lifestyle Intervention for Diabetes and Weight Management in Psychosis (clinicaltrials.gov) -  Jun 18, 2016   
    P=N/A,  N=120, Completed, 
    N=72 --> 18 | Recruiting --> Terminated Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> May 2015
  • ||||||||||  iloperidone / Generic mfg.
    Trial completion, Trial primary completion date:  Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients (clinicaltrials.gov) -  Jun 13, 2016   
    P1,  N=33, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2016 --> Feb 2017 Active, not recruiting --> Completed | Trial primary completion date: Aug 2015 --> Feb 2015
  • ||||||||||  iloperidone / Generic mfg.
    Trial completion, Trial primary completion date:  REPRIEVE: Relapse Prevention Study in Patients With Schizophrenia (clinicaltrials.gov) -  Jun 13, 2016   
    P3,  N=303, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Aug 2015 --> Feb 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Mar 2015
  • ||||||||||  aripiprazole / Generic mfg., amisulpride / Generic mfg.
    Trial completion:  Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS) (clinicaltrials.gov) -  May 26, 2016   
    P=N/A,  N=136, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Mar 2015 Active, not recruiting --> Completed
  • ||||||||||  Enrollment closed, Trial primary completion date, Head-to-Head:  TaSCS: Task Sharing for the Care of Severe Mental Disorders in a Low-income Country (clinicaltrials.gov) -  May 24, 2016   
    P3,  N=324, Active, not recruiting, 
    Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Feb 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Jun 2017
  • ||||||||||  Trial primary completion date:  Cognitive Remediation of Schizophrenia in a Community Mental Health Setting (clinicaltrials.gov) -  May 16, 2016   
    P=N/A,  N=120, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Jun 2017 Trial primary completion date: Nov 2015 --> Jun 2016
  • ||||||||||  Enrollment closed, Trial primary completion date:  CAST: Optimizing Cognitive Remediation Outcomes in Schizophrenia (clinicaltrials.gov) -  May 16, 2016   
    P=N/A,  N=160, Active, not recruiting, 
    Trial primary completion date: Nov 2015 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> May 2016
  • ||||||||||  Trial primary completion date:  Adaptive Treatment for Adolescent Cannabis Use Disorders (clinicaltrials.gov) -  May 13, 2016   
    P=N/A,  N=172, Active, not recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Feb 2016 --> Jul 2016
  • ||||||||||  Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
    Trial primary completion date:  ReLiAM: Real Life Assessment of Abilify Maintena (clinicaltrials.gov) -  May 5, 2016   
    P=N/A,  N=252, Recruiting, 
    Trial primary completion date: Apr 2012 --> Dec 2016 Trial primary completion date: May 2016 --> Aug 2016
  • ||||||||||  Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes, Aristada two-month (aripiprazole lauroxil XR) / Alkermes
    Trial completion, Trial primary completion date:  An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia (clinicaltrials.gov) -  May 3, 2016   
    P1,  N=140, Completed, 
    Suspended --> Completed | N=1050 --> 830 | Trial primary completion date: Sep 2016 --> Oct 2015 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Apr 2016
  • ||||||||||  JNJ-39393406 / J&J
    Trial primary completion date:  Novel Smoking Cessation Drug for Schizophrenia (clinicaltrials.gov) -  May 2, 2016   
    P2,  N=60, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Apr 2016 Trial primary completion date: Sep 2016 --> Apr 2017
  • ||||||||||  Enrollment change:  ASCI: Social Cognition Intervention (clinicaltrials.gov) -  Apr 25, 2016   
    P=N/A,  N=157, Completed, 
    Trial primary completion date: May 2015 --> Nov 2016 N=105 --> 157